1611-75-2

Upstream product

• 109-74-0 propyl cyanide 
• 2845-89-8 1-chloro-3-methoxy-benzene 
• 68266-31-9 1-chloro-1-(3-methoxyphenyl)propane 
• 151-50-8 potassium cyanide 
• 74-96-4 ethyl bromide 
• 19924-43-7 3-methoxyphenylacetonitrile 
• 52956-27-1 1-(3-methoxyphenyl)propanol 
• 591-31-1 3-methoxy-benzaldehyde 
• 109-72-8 n-butyllithium 
• 75-03-6 ethyl iodide 
• 108-18-9 diisopropylamine 

Downstream Products

• 92577-77-0 (3-Methoxyphenyl)ethylisopropylacetonitril 
• 222191-16-4 2-(3-methoxyphenyl)butanoic acid 
• 27180-90-1 3-ethyl-3-(3-methoxyphenyl)azepane 
• 123312-25-4 2-(3-methoxyphenyl)-1-butanamine 
• 95024-79-6 N-(2-Pentyl)-2-(3-methoxyphenyl)-2-ethyl-3-methylbutylamin 
• 95024-78-5 N-(3-Pentyl)-2-(3-methoxyphenyl)-2-ethyl-3-methylbutylamin 
• 95024-77-4 N-(3-Methyl-2-butyl)-2-(3-methoxyphenyl)-2-ethyl-3-methylbutylamin 
• 95170-03-9 N-(2-Pentyl)-2-(3-hydroxyphenyl)-2-ethyl-3-methylbutylamin 
• 95170-01-7 N-(3-Pentyl)-2-(3-hydroxyphenyl)-2-ethyl-3-methylbutylamin 
• 95169-99-6 N-(3-Methyl-2-butyl)-(3-hydroxyphenyl)-2-ethyl-3-methylbutylamin 
• 95169-87-2 N-sec-Butyl-2-(3-methoxyphenyl)-2-ethyl-3-methylbutylamin 
• 94824-59-6 N-sec-Butyl-2-(3-hydroxyphenyl)-2-ethyl-3-methylbutylamin 
• 94824-56-3 N-Isopropyl-2-(3-methoxyphenyl)-2-ethyl-3-methylbutylamin 
• 94329-39-2 N-Isopropyl-2-(3-hydroxyphenyl)-2-ethyl-3-methylbutylamin 

Relevant academic research and scientific papers

3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to 3-ethyl-3-phenylazepane derivatives having dual pharmacological activity towards both the sigma (σ) receptor and the μ- opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions compris

Benzazine derivatives as phosphodiesterase 4 inhibitors

Compounds of formula I: wherein A is a heterocycle containing a nitrogen atom and optionally saturated or unsaturated and optionally further substituted by an oxo group (═O); R is: hydrogen, cyano, (C1-4)alkoxycarbonyl, carbamoyl; optionally substituted (C4-7)-cycloalkyl, aryl or heterocycle; (C1-8)alkyl, (C2-8)alkenyl or (C2-8)alkynyl optionally branched and/or substituted by (C4-7) cycloalkyl, aryl or heterocycle; aryloxy, heterocyclyloxy, aryl(C1-4)alkoxy, heterocyclyl(C1-4)alkoxy, amino substituted by one or two (C1-4)alkyl group(s), aryl-amino, heterocyclyl-amino, aryl(C1-4)alkyl-amino, or heterocyclyl(C1-4)alkylamino; Y is methylene or ethylene; W is an optionally substituted aryl or heterocycle; R1is hydrogen, (C4-7)cycloalkyl or a (C2-8)alkyl, (C2-8)alkenyl or (C2-8)alkynyl group optionally substituted by hydroxy, oxo, (C4-7)cycloalkyl, aryl or heterocycle, and optionally interrupted by one or more heteroatom(s) or heterogroup(s); R2is a (C1-6)alkyl or polyfluoro(C1-6)alkyl group; the N→O derivatives of the compounds of formula I and the pharmaceutically acceptable salts thereof. The compounds of formula (I) are PDE 4 inhibitors and may be used in compositions and methods involving PDE 4 inhibition.

ALPHA, ALPHA DIALKYLBENZYL DERIVATIVES

The invention concerns (alpha),(alpha)-dialkylbenzyl derivatives of the formula I wherein Ar1 is phenyl or naphthyl, or a 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur; A1 is a direct link to X1 or is (1-3C)alkylene; X1 is oxy, thio, sulphinyl or sulphonyl; the phenylene group may optionally bear one or two substituents R3; each of R1 and R2, which may be the same or different, is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, fluoro-(1-4C)alkyl, phenyl or phenyl-(1-4C)alkyl, provided that both of R1 and R2 are not methyl or fluoromethyl; and Q is cyano, amino, nitro, formyl, (1-4C)alkoxy, thiazolyl or (2-4C)alkanoyl; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors